This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
Patients or their guardians understand and voluntarily sign the informed consent form, and are expected to complete the follow-up examinations and treatments as required by the study protocol.
History of other malignancies within 3 years prior to screening, except for adequately treated cervical carcinoma in situ, papillary thyroid carcinoma, basal cell or squamous cell skin carcinoma, locally treated prostate cancer after radical treatment, and ductal carcinoma in situ after radical treatment.
Single group
CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation
DrugCLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation
Overall survival
Click on the lead sponsor to view all of their trials.
Donghua Zhang
Lead sponsor
Tongji Hospital
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
